Search

Your search keyword '"FRANKE, CATHERINE"' showing total 18 results
Start Over Author "FRANKE, CATHERINE"
18 results on '"FRANKE, CATHERINE"'

4. PREFACE

Author

Franke, Catherine Anne

Published
1989

6. A Novel Class of Cyclic .beta.-Dicarbonyl Leaving Groups and Their Use in the Design of Benzisothiazolone Human Leukocyte Elastase Inhibitors

Author

Hlasta, Dennis J., primary, Ackerman, James H., additional, Court, John J., additional, Farrell, Robert P., additional, Johnson, Judith A., additional, Kofron, James L., additional, Robinson, David T., additional, Talomie, Timothy G., additional, Dunlap, Richard P., additional, and Franke, Catherine A., additional

Published
1995
Full Text
View/download PDF

8. Biological activity of WIN 63759, an orally bioavailable inhibitor of human neutrophil elastase

Author

Silver, Paul J., primary, Gordan, Robert J., additional, Pagani, Edward D., additional, Johnson, Judith A., additional, Maycock, Alan L., additional, Dunlap, Richard P., additional, Ferguson, Edward W., additional, Franke, Catherine A., additional, Drozd, Marion L., additional, Robinson, David T., additional, Mark Eickhoff, W., additional, Baizman, Eugene R., additional, Subramanyam, Chakrapani, additional, Desai, Ranjit C., additional, Hlasta, Dennis J., additional, and Newton, John F., additional

Published
1995
Full Text
View/download PDF

9. Orally Bioavailable Benzisothiazolone Inhibitors of Human Leukocyte Elastase

Author

Hlasta, Dennis J., primary, Subramanyam, Chakrapani, additional, Bell, Malcolm R., additional, Carabateas, Philip M., additional, Court, John J., additional, Desai, Ranjit C., additional, Drozd, Marion L., additional, Eickhoff, W. Mark, additional, Ferguson, Edward W., additional, Gordon, Robert J., additional, Dunlap, Richard P., additional, Franke, Catherine A., additional, Mura, Albert J., additional, Rowlands, Anne, additional, Johnson, Judith A., additional, Kumar, Virendra, additional, Maycock, Alan L., additional, Mueller, Karl R., additional, Pagani, Edward D., additional, Robinson, David T., additional, Saindane, Manohar T., additional, Silver, Paul J., additional, and Subramanian, Sandhya, additional

Published
1995
Full Text
View/download PDF

12. The design of potent and stable benzisothiazolone inhibitors of human leukocyte elastase

Author

Hlasta, Dennis J., primary, Bell, Malcolm R., additional, Court, John J., additional, Cundy, Kenneth C., additional, Desai, Ranjit C., additional, Ferguson, Edward W., additional, Gordon, Robert J., additional, Kumar, Virendra, additional, Maycock, Alan L., additional, Subramanyam, Chakrapani, additional, Dunlap, Richard P., additional, Eiff, Shari L., additional, Franke, Catherine A., additional, Mura, Albert J., additional, and Rowlands, Anne G., additional

Published
1995
Full Text
View/download PDF

18. Mechanism of inhibitation of human leukocyte elastase by benzisothiazolinone-1,1-dioxides

Author

Franke, Catherine

Subjects
Chemistry
Abstract

Benzisothiazolinone- 1,1 -dioxides are potent, time-dependent, reversible inhibitors of human leukocyte elastase (HLE) that demonstrate the ability to inhibit HLE catalyzed degradation of insoluble elastin. A stoichiometry of 1.4 to 1.47 equivalents per mole of enzyme indicates that these compounds are efficient inhibitors of HLE. The proposed mechanism of HLE inhibition has been investigated and the data are consistent with acylation of the active site serine followed by elimination of the leaving group to form a reactive sulfonyl imine intermediate. The reactive intermediate can undergo hydration followed by deacylation or it can react with an enzyme nucleophile to form a stable enzyme-inhibitor complex that slowly reactivates. Initial velocities in the presence and absence of inhibitor are identical, establishing that the reversible formation of a Michaelis complex does not occur prior to covalent interaction between the enzyme and inhibitor. The leaving group is released in a kinetically competent step without an induction period. The lack of a secondary deuterium isotope effect on inactivation kinetics is consistent with rate limiting forward acylation. Reactivation is independent of leaving group variations, suggesting the formation of a common enzyme-inhibitor complex and a common reactivation pathway through the same rate determining step. The product of reactivation is the 4-isopropyl-6- methoxysaccharin. Initially, 30% forms within 5 minutes while the remainder forms slowly over 4 days. This is consistent with partitioning between reactivation and crosslinking the enzyme active site serine and histidine. Even the crosslinked enzyme has an important reactivation pathway whereby the enzyme regains full activity. Thus, this class of compounds may offer several advantages over other types of HLE inhibitors as potential therapeutic agents in the treatment of inflammatory pulmonary diseases.

Published
1995

Catalog

Books, media, physical & digital resources
See catalog results